Capsida Biotherapeutics has halted its phase I/II clinical trial for gene therapy CAP-002 targeting STXBP1 encephalopathy after the death of the first patient enrolled. The pause aims to investigate the cause and ensure patient safety as the company works with researchers and the affected community. This setback highlights the challenges in developing gene therapies for rare neurological disorders, where clinical trials must carefully balance potential benefits against risks.